|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||37.41 / 51.88|
Shareholders of the oncology drug maker ought to be satisfied with the auction's conclusion.
Pfizer's $14 billion acquisition of Medivation is a strong purchase, according to Jim Cramer, who now wonders what Sanofi will do next.
PFE is trading up on the announcement, and the deal should add to earnings in 2017.
Pfizer confirmed its $14 billion acquisition of cancer drugmaker Medivation on Monday.
Pfizer finalizes a deal to buy cancer drugmaker Medivation; ChemChina gets U.S. approval for its takeover of Syngenta; Viacom CEO Philippe Dauman is ousted.
Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.
Earlier this month the two major pharmacy benefit managers, CVS Caremark CVS and Express Scripts ESRX released lists of drugs they will no longer cover in 2017.
The beaten-down biotech sector is making an impressive comeback. The sector seems to be rebounding after tumbling by more than 40%.
The sector seems to be rebounding after tumbling by more than 40%.
The alternate reality mobile gaming app has been downloaded over 75 million times in less than a month.
The mobile-gaming market is expected to surpass console games this year, according to Deloitte.
Alphabet shares rise after the company handily beats quarterly estimates; Amazon's cloud computing business continues to shine; U.S. stock futures point lower.
GDP growth in the eurozone slowed in the second quarter.
Sanofi says currency headwinds will erode 4% from full-year earnings per share.
Our first upside target is the $50 to $52 area and a close below $40 would extend the base.
Sanofi (SNY) stock is declining on Thursday afternoon ahead of the company’s 2016 second quarter results, due out before tomorrow’s market open.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMOT, ANGI, CBT, ELY, FTAI, GNBC, LOGM, NCR, SIX, SKUL, SLAB, SNY, SONS, TRK, TRN, UFS, VRTX, WES, ZNGA Downgrades: AF, BA, TER, WEX Initiations: FSV Read on to get TheStreet Quant Ratings' detailed report:
- AdlyxinTM is approved as Lyxumia® in more than 60 countries -
- World's largest influenza vaccine manufacturer expects to distribute more than 65 million vaccine doses to help protect people six months and older against the flu -
The company sans CEO Scangos needs to do some type of deal in the coming months.
Investors may want to look at some small-cap pharma names that could be takeover targets like Relypsa.
Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.
Shares of Relypsa are rallying after the company announced it has agreed to be acquired by Galenica Group in a $1.53B deal.
Trade-Ideas LLC identified Sanofi (SNY) as a pre-market mover with heavy volume candidate
Trade-Ideas LLC identified Sanofi (SNY) as a "storm the castle" (crossing above the 200-day simple moving average on higher than normal relative volume) candidate
Falkner has joined forces with Regeneron and Sanofi Genzyme in collaboration with leading dermatology organizations to educate Americans about a potentially serious, chronic inflammatory skin disease known as atopic dermatitis.
Drugmaker Sanofi Pasteur has struck up a deal with the U.S. Army to come up with a vaccine for the Zika virus.